(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 7 March 2002 (07.03.2002)

PCT

(10) International Publication Number WO 02/018404 A3

Brian, William; 15 Vesta Avenue, St. Albans, Hert-

fordshire AL1 2PJ (GB). HOBBS, Christopher, John; 9 Magnolia Close, Hertford, Hertfordshire SG13 7UR

(GB). JIANG, Wen-Rong; 20 Salmon Close, Welwyn Garden City, Hertfordshire AL7 1TR (GB). MARTIN.

Joseph, Armstrong; 10 The Chownes, West Common, Harpenden, Herts AL5 2BN (GB). MERRETT, John,

Herbert; 23 Bush Spring, Baldock, Hertfordshire SG7 6QT (GB). NAJERA, Isabel; 49 Salisbury Avenue, St.

Albans, Hertfordshire AL1 4TZ (GB). SHIMMA, Nobuo; Higashikaigan-Minami 2-11-19, Chigasaki-shi, Kana-

gawa-ken 253-0054 (JP). TSUKUDA, Takuo; 540-22

(51) International Patent Classification?: C07H 19/06, 19/16, A61K 31/7064, 31/7076, A61P 31/14

(21) International Application Number: PCT/EP01/09633

(22) International Filing Date: 21 August 2001 (21.08.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0021285.2

30 August 2000 (30.08.2000) GB

0026611.4 31 October 2000 (31.10.2000) GB

(71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; 124, Grenzacherstrasse, CH-4070 Basle (CH).

(74) Agent: RAUBER, Beat; 124 Grenzacherstrasse, CH-4070 Basle (CH).

Rensyoji, Odawara-shi, Kanagawa-ken 250-0865 (JP).

(72) Inventors: DEVOS, Rene; 4 Salmon Close, Welwyn Garden City, Hertfordshire AL7 1TR (GB). DYMOCK, (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

[Continued on next page]

(54) Title: NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C

Use of compounds of formula I

(57) Abstract: Use of compounds of formula (I), wherein R1 is hydrogen, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyano, isocyano or azido; R2 is hydrogen, hydroxy, alkoxy, chlorine, bromine or iodine; R3 is hydrogen; or R2 and R3 together represent =CH2; or R2 and R3 represent fluorine; X is O, s or CH₂; a, b, c, d denoting asymmetric carbon atoms each of which is substituted with 4 different substituents; and B signifies a purine base B1 which is connected through the 9-nitrogen of formula (B1), wherein R4 is hydrogen, hydroxyl, alkyl, alkoxy, alkylthio, aryloxy, arylthio, heterocyclyl, NR7R8, halogen or SH; R5 is hydrogen, hydroxy, alkyl, haloalkyl, cycloalkyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, heterocyclyl, heterocyclylamino, halogen, NR7R8, NHOR9, NHNR7R8 or SH; R6 is hydrogen, hydroxy, alkyl, alkoxy, alkylthio, aryloxy, arylthio, heterocyclyl, NR7R8, halogen, SH or cyano; R7 and R8 are independently of each other hydrogen, alkyl, aryl, hydroxyalkyl, alkenylalkyl, alkynylalkyl, cycloalkyl or acyl; R9 is hydrogen, alkyl or aryl; or B signifies an oxidised purine base B2 which is connected through the 9-nitrogen of formula (B2), wherein R4, R5 and R6 are as defined above; or B signifies a purine base B3 which is connected through the 9-nitrogen of formula (B3), wherein R4 and R6 are as defined above; R10 is hydrogen, alkyl or aryl; Y is O, S or NR11; R11 is hydrogen, hydroxy, alkyl, OR9, heterocyclyl or NR7R8; R7, R8 and R9 are as defined above; or B signifies a pyrimidine base B4 which is connected through the 1-nitrogen of formula (B4), wherein Z is O or S; R12 is hydrogen, hydroxy, alkyl, alkoxy, haloalkyl, alkylthio, aryl, aryloxy, arylthio, heterocyclyl, heterocyclylamino, halogen, NR7R8, NHOR9, NHNR7R8 or SH; R13 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, cycloalkyl or halogen; R7, R8 and R9 are as defined above; or B signifies a pyrimidine base B5 which is connected through the 1-nitrogen of formula (B5), wherein Y, Z, R¹⁰ are as defined above for the treatment of diseases mediated by the Hepatitis C Virus (HIV) or for the preparation of a medicament for such treatment. The invention is concerned with novel and known purine and pyrimidine nucleoside derivatives, their use as inhibitors of subgenomic Hepatitis C Virus (HCV) RNA replication and pharmaceutical compositions of such compounds.





CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report: 14 November 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A. CLASSI IPC 7	FICATION OF SUBJECT MATTER C07H19/06 C07H19/16 A61K31/7	7064 A61K31/7076	A61P31/14
According to	o International Patent Classification (IPC) or to both national classific	ation and IPC	
	SEARCHED		
	ocumentation searched (classification system followed by classification CO7H A61K A61P	ion symbols)	
	tion searched other than minimum documentation to the extent that s		
	ala base consulted during the international search (name of data ba ternal, WPI Data, PAJ, CHEM ABS Data	·	ems usero)
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the rel	levant passages	Relevant to claim No.
X	WO 94 01443 A (WELLCOME FOUND ;KO GEORGE WALTER (US); DRAANEN NANIN 20 January 1994 (1994-01-20) examples claims page 3, paragraph 3		1,2,5,6,
X	WO 98 16184 A (ICN PHARMACEUTICAL DEVERON (US); TAM ROBERT (US); WA 23 April 1998 (1998-04-23) examples claims page 11, line 14	S;AVERTT ANG GU)	1,15,16
X Furth	ner documents are listed in the continuation of box C.	χ Patent family members a	are listed in annex.
Special cal	tegories of cited documents :	"T" later document published afte	r the international filing date
consider d "E" earlier d filing d	nt defining the general state of the art which is not ered to be of particular relevance locument but published on or after the International	or priority date and not in conciled to understand the princinvention "X" document of particular relevant cannot be considered novel	nflict with the application but iple or theory underlying the nce; the claimed invention
which i citation "O" docume other n	s cited to establish the publication date of another or or other special reason (as specified) and referring to an oral disclosure, use, exhibition or neans	"Y" document of particular relevant cannot be considered to invo- document is combined with of ments, such combination being.	
P docume later th	nt published prior to the international filling date but an the priority date claimed	in the art. *&" document member of the sam	ne patent family
	July 2002	Date of mailing of the interna	·
		2 6. 0	7. 2002
Name and m	nalling address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	de Nooy, A	

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 55 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. X Claims Nos.: . 43,49-57 (all partially) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This international Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As a result of the prior review under R. 40.2(e) PCT, no additional fees are to be refunded.
1. X As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 43,49-57 (all partially)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty for claim 43. So many documents were retrieved that it is impossible to determine which parts of the claim may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, it appears impossible to execute a meaningful search and/or to issue a complete search report over the whole breadth of the claims. Consequently, the search and the report for this claim has been restricted to the case where R13'''' is an alkyl but not methyl.

Present claims 49-57 relate to an extremely large number of compounds. In fact, the claims contain so many options, that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the above mentioned claims have been searched insofar as the compounds of claim 49 fall within earlier compound claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1 (in part), 3-4 (in part), 12-13 (in part), 14, 34, 35, 50-56 (in part)

Compounds of Formula I-a of claim 34 where B'=B2-a of claim 34, and uses, compositions and processes pertaining thereto.

2. Claims: 1 (in part), 3-4 (in part), 15-16 (in part), 17, 36, 37, 50-56 (in part)

Compounds of Formula I-b of claim 36 where B'' = B3-a of claim 36, and uses, compositions and processes pertaining thereto.

3. Claims: 1-4 (in part), 18-25 (in part), 26, 27-28 (in part), 29, 38-42, 50-56 (in part)

Compounds of Formula I-c of claim 38 where B''' = B4-a of claim 38, compounds of Formula I-d of claim 40 where B''' = B4-b of claim 40 or 41, and uses, compositions and processes pertaining thereto.

4. Claims: 1-4 (in part), 30-32 (in part), 33, 43-48, 50-56 (in part)

Compounds of Formula I-e of claim 43 where B'''' = B5-a of claim 43, compounds of Formula I-f of claim 45 where B'''' = B5-b of claim 45, compounds of Formula I-g of claim 47 where B'''' = B5-c of claim 47 and uses, compositions and processes pertaining thereto.

5. Claims: 1-4 (in part), 5-10, 12-13 (in part), 15-16 (in part), 18-25 (in part), 27-28 (in part), 30-32 (in part), 55-56 (in part)

Use of compounds of the above mentioned claims which do not fall within one of the previous subjects for the treatment of Hepatitis C Virus or for the preparation of a medicament for such treatment.

Category °	etion) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.	
Category	Citation of document, with indication, where appropriate, of the relevant passages	Helevani to claim No.	
x	WO 94 05687 A (UNIV BIRMINGHAM; WELLCOME FOUND (GB); MILLER JOHN ALLEN (GB); YOUN) 17 March 1994 (1994-03-17) examples claims page 4, line 22 - line 36	1,2, 30-32	
А	EP 0 468 352 A (NIPPON KAYAKU KK) 29 January 1992 (1992-01-29) examples claims page 14, line 17	. 1	
Х	US 5 102 873 A (MONTGOMERY JOHN A ET AL) 7 April 1992 (1992-04-07) example 3	34	
Х	US 4 755 594 A (BRIDGES ALEXANDER J ET AL) 5 July 1988 (1988-07-05) example 4	34	
X	P.J.M. VAN GALEN ET AL.: "A binding site model and structure-activity relationships for the rat A3 adenosine receptor" MOLECULAR PHARMACOLOGY, vol. 45, 1994, pages 1101-1111, XP008000722 compound 30	34	
A	US 5 998 387 A (SCAMMELLS PETER J ET AL) 7 December 1999 (1999-12-07) figure 2	34	
A	K. MIURA ET AL.: "Chemical conversion of adenosine to guanosine (Nucleosides and nucleotides. XI)" CHEM. PHARM. BULL., vol. 23, 1975, pages 464-466, XP002190612 chart 1	34	
X	W.M. HAMMARGREN ET AL.: "Identification of a novel nucleoside, 1,N6-dimethyladenosine, in human cancer urine" ANALYTICA CHIMICA ACTA, vol. 247, 1991, pages 201-209, XP008005307 compound 1	36	
x	US 3 891 623 A (VORBRUGGEN HELMUT ET AL) 24 June 1975 (1975-06-24) examples 2,3	38	

		PC1/EP 01/09633
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	H. VORBRÜGGEN ET AL.: "Eine neue einfache Synthese von Cytidinen" LIEBIGS ANN. CHEM., 1975, pages 988-1002, XP002204034 compound 19	38
X	XX. ZHOU ET AL.: "Pyridyl groups for protection of the imide functions of uridine and guanosine. Exploration of their displacement reactions for site-specific modifications of uracil and guanine bases" ACTA CHEMICA SCANDINAVICA B, vol. 40, 1986, pages 806-816, XP002204035 the whole document	38
X	R.W. MILES ET AL.: "Nucleic acid related compounds. 87. Nucleophilic functionalization of cytidine and 2'-deoxycytidine derivatives via elaboration of the 4-amino group into a readily displaced 1,2,4-triazol-4-yl substituent" J. ORG. CHEM., vol. 60, 1995, pages 7066-7069, XP002204036 compounds 3,4	38
X	G.E. KEYSER ET AL.: "Iodomethylethers from 1,3-dioxolane and 1,3-oxothiolane: preparation of acyclic nucleoside analogs" TETRAHEDRON LETTERS, 1979, pages 3263-3264, XP002204037 compound 3	38
x	US 4 526 988 A (HERTEL LARRY W) 2 July 1985 (1985-07-02) the whole document	40
X	HERTEL L W: "SYNTHESIS OF 2-DEOXY-2,2-DIFLUORO-D-RIBOSE AND 2-DEOXY-2,2-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDES" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 53, no. 11, 27 May 1988 (1988-05-27), pages 2406-2409, XP000572745 ISSN: 0022-3263 the whole document -/	
		•

		PC1/E1 01/09033		
C.(Continua Category •	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Calegory	Citation of document, with indication, where appropriate, of the relevant passages	Helevalli to dalifi No.		
X	CHOU T S ET AL: "STEREOSPECIFIC SYNTHESIS OF 2-DEOXY-2,2-DIFLUORORIBONOLACTONE AND ITS USE IN THE PREPARATION OF 2'-DEOXY-2'.2'-DIFLUORO-BETA-D-RIBOFURANOS YL PYRIMIDINE NUCLEOSIDES: THE KEY ROLE OF SELECTIVE CRYSTALLIZATION" SYNTHESIS, GEORG THIEME VERLAG. STUTTGART, DE, no. 6, 1 June 1992 (1992-06-01), pages 565-570, X?000572747 ISSN: 0039-7881 compounds 1,16	40		
X	KOTRA L P ET AL: "STRUCTURE-ACTIVITY RELATIONSHIPS OF 2'-DEOXY-2',2'-DIFLUORO-L-ERYTHRO-PENTOFURANOSYL NUCLEOSIDES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 22, 1997, pages 3635-3644, XP000867642 ISSN: 0022-2623 compounds 43-52	40		
X	KOTRA L P ET AL: "Synthesis of 2,3-dideoxy-2,2-difluoro-1-glycero-pentofu ranosyl nucleosides" CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 306, no. 1-2, January 1998 (1998-01), pages 69-80, XP004204788 ISSN: 0008-6215 scheme 1	40		
X	M. SEKINE, T. NAKANISHI: "Facile synthesis of 3'-O-methylthymidine and 3'-deoxythymidine and related deoxygenated thymidine derivative: A new method for selective deoxygenation of secondary hydroxy groups" J. ORG. CHEM., vol. 55, 1990, pages 924-928, XP002204038 compound 2	43		
X	A. HAMPTON ET AL.: "Species- or Isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes" J. MED. CHEM., vol. 25, 1982, pages 644-649, XP002204039 compounds 7d,e	43		

	<u> </u>	PCT/EP 01/09633		
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT			
Calegory °	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	S. EL-KOUSY ET AL.: "Synthesis and investigation of antiviral activity of 3'-0-(aminoalkyl)-thymidines and their quarternary ammonium salts" MONATSHEFTE FÜR CHEMIE, vol. 125, 1994, pages 713-721, XP002204040 compounds 4a-d, 6a-d	43		
X	N.K. KOCHETKOV ET AL.: "The mechanism of the reaction of hydroxylamine and O-methylhydroxylamine with cytidine" TETRAHEDRON LETTERS, 1967, pages 3253-3257, XP002204041 compound 4a	47,48		
E	WO 01 90121 A (NOVIRIO PHARMACEUTICALS LTD; UNI DEGLI STUDI DI CAGLIARI (IT); LAC) 29 November 2001 (2001-11-29) the whole document	1-57		

		tent document in search report		Publication		Dotont family	
-		<u> </u>		date		Patent family member(s)	Publication date
	WO	9401443	Α	20-01-1994	AU	4508593 A	31-01-1994
					CA	2139132 A1	20-01-1994
					CN	1087089 A	25-05-1994
					EΡ	0648218 A1	19-04-1995
					WO	9401443 A1	20-01-1994
					JP	7508531 T	21-09-1995
					MX	9303985 A1	28-02-1994
					ZA	9304742 A	03-01-1995
	WO	9816184	Α	23-04-1998	AU	727177 B2	07-12-2000
			•		AU	4899997 A	11-05-1998
					BR	9714349 A	14-11-2000
					CA	2322053 A1	16-07-1998
					CA	2323791 A1	23-04-1998
					CN	1286258 A	07-03-2001
					CN	1296011 A	23-05-2001
					CN	1233254 A	27-10-1999
					CZ	9901267 A3	14-07-1999
					EP	1072607 A2	31-01-2001
					EP	0961775 A2	08-12-1999
					HU	0001186 A2	28-05-2001
					JP	2001524936 T	04-12-2001
					JP	2002105096 A	10-04-2002
					NO	991784 A	15-06-1999
					NO	20004326 A	15-06-1999
					NO	20004328 A	15-06-1999
					NZ	505531 A	31-08-2001
					NZ	505553 A	30-11-2001
					NZ	505554 A	30-11-2001
					PL	332694 A1	27-09-1999
					SI	20024 A	29-02-2000
					SK	48199 A3	18-01-2000
					US	2002058635 A1	16-05-2002
					WO	9816184 A2	23-04-1998
			•		AU	736075 B2	26-07-2001
					AU	6023898 A	03-08-1998
					BR	9807473 A	21-03-2000
					CN	1312254 A	12-09-2001
					CN	1289594 A	04-04-2001
					CN Ep	1253504 T 1103559 A1	17-05-2000 30-05-2001
					EP	0998293 A1	30-05-2001 10-05-2000
					HU	0998293 A1 0001526 A2	28-05-2000 28-05-2001
					JP	2002515892 T	
					JP	2002080490 A	28-05-2002
						2002080490 A 993439 A	19-03-2002
					NO		13-09-1999 13-09-1999
					NO	20004327 A 20004329 A	
					NO		13-09-1999
				•	PL cr	336579 A1	03-07-2000
		•			SI	9820003 A	30-06-1999
					SK WO	94099 A3 9830223 A1	11-06-2001 16-07-1998
	₩ ∩	 9405687	Α	17-03-1994	AU	4973393 A	29-03-1994
	NO :	J-100001	п	11 00 1997	CA	2143834 A1	17-03-1994
					EP	0658166 A1	21-06-1995
					WO	9405687 A1	17-03-1994
					JP	8504753 T	21-05-1996

				- FUITER	01/09633
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0468352	A	29-01-1992	AU CA CN EP JP	642031 B2 8125391 A 2047644 A1 1059524 A ,B 0468352 A2 5001044 A	07-10-1993 30-01-1992 25-01-1992 18-03-1992 29-01-1992 08-01-1993
			US	5374625 A	20-12-1994
US 5102873	A	07-04-1992	NONE		
US 4755594	А	05-07-1988	AU CA	592728 B2 6797287 A 1270821 A1	18-01-1990 06-08-1987 26-06-1990
			DK EP FI	46687 A 0232813 A2 870371 A	01-08-1987 19-08-1987 01-08-1987
			KR	9100602 B1	28-01-1991
			NO NZ	870390 A ,B, 219128 A	03-08-1987
			NZ PH	219128 A 23342 A	29-01-1990 14-07-1989
			PT	84226 A ,B	01-02-1987
			JP ZA	62228095 A 8700120 A	06-10-1987 31-08-1988
US 5998387	Α	07-12-1999	US US	5736528 A 5631260 A	07-04-1998 20-05-1997
			US	5446046 A	29-08-1995
			AU	728439 B2	11-01-2001
			AU BR	1522097 A 9612324 A	28-07-1997 28-12-1999
			CA	2238736 A1	10-07-1997
			EP JP	1019426 A1 2000502712 T	19-07-2000 07-03-2000
			NZ	326608 A	28-04-2000
			NZ	502628 A	29-06-2001
			WO US	9724363 A1 5668139 A	10-07-1997 16-09-1997
			AT	187726 T	15-01-2000
			AU	699630 B2	10-12-1998
			AU CA	1044995 A 2172726 A1	22-05-1995 04-05-1995
			DE	69422191 D1	20-01-2000
			DE DK	69422191 T2 725782 T3	25-05-2000 13-06-2000
			EP	0725782 A1	14-08-1996
			ES	2141913 T3	01-04-2000
			GR JP	3032730 T3 9507052 T	30-06-2000 15-07-1997
			JP	2002105094 A	10-04-2002
			PT WO	725782 T 9511904 A1	31-05-2000 04-05-1995
US 3891623	A	24-06-1975	DE	2122991 A1	16-11-1972
			BE CH	783026 A1 579585 A5	06-11-1972 15-09-1976
			U11	כא כסניבוני	
			CS FR	171723 B2 2135249 A5	29-10-1976 15-12-1972

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 3891623	Α		NL	7206058 A	07-11-1972
US 4526988	Α	02-07-1985	AT	29726 T	15-10-1987
			AU	565856 B2	01-10-1987
			AU	2537484 A	13-09-1984
			BG	40814 A3	16-02-1987
			CA	1218647 A1	03-03-1987
			CA	1223869 C	07-07-1987
			CS	246075 B2	16-10-1986
			CY	1489 A	08-12-1989
			DD	216468 A5	1212-1984
			DE	3466224 D1	22-10-1987
			DK	114484 A ,B,	11-09-1984
			DK	190590 A	10-08-1990
			EP	0122707 A1	24-10-1984
			ES	530364 D0	01-12-1985
			FI	840890 A ,B,	11-09-1984
			· GB	2136425 A ,B	19-09-1984
•			GB	2172287 A ,B	17-09-1986
			GR	81845 A1	12-12-1984
			HK	44989 A	09-06-1989
			ΗÙ	193893 B	28-12-1987
			ΙE	57071 B1	22-04-1992
			ÎĹ	71143 A	31-07-1988
			ĨĹ	80463 A	31-07-1988
			ĴΡ	1986188 C	08-11-1995
			JP	6009602 A	18-01-1994
			ĴΡ	6102655 B	14-12-1994
			JP	1833350 C	29-03-1994
			ĴΡ	5042438 B	28-06-1993
			JP	59175498 A	04-10-1984
			KE	3874 A	30-06-1989
			KR	8601283 B1	05-09-1986
			LÜ	88791 A9	05-11-1996
			MX	9203246 A1	31-07-1992
			NZ	207358 A	06-03-1987
			PH	23240 A	06-06-1989
			PH	23593 A	11-09-1989
			PL	246601 A1	13-08-1985
			PT	78181 A ,B	01-04-1984
			ŔŎ	89963 A1	30-09-1986
			SG	21889 G	14-07-1989
			SÜ	1442076 A3	30-11-1988
			ÜS	4808614 A	28-02-1989
			US	5015743 A	14-05-1991
			US	5118820 A	02-06-1992
			US	4692434 A	08-09-1987
			ZA	8401605 A	30-10-1985
WO 0190121	A	29-11-2001	AU	7490601 A	03-12-2001
			WO	0190121 A2	29-11-2001